In July of this year, I was invited to volunteer for an important phase 3 coronavirus disease 2019 (COVID-19) vaccine trial in Boston. As a semiretired physician, I was thrilled to be able to contribute to science, support my colleagues, and hasten the discovery of a vaccine to help end this terrible pandemic.
While doing background research on the vaccine and its parent company, I learned that some company executives sold extra shares of stock just as the first positive press releases came out, and then sold additional shares following publication of the phase 2 study.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Becker C. Relationships Between Academic Medicine Leaders and Industry—Time for Another Look? JAMA. 2020;324(18):1833–1834. doi:10.1001/jama.2020.21021
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: